Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Capecitabine for Hormone Receptor‐positive Versus Hormone Receptor‐negative Breast Cancer." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Prophylactic_vaccination_against_human_papillomaviruses_to_prevent_cervical_cancer_and_its_precursors:_Cochrane_systematic_review. Accessed 20 April 2024.
Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Prophylactic_vaccination_against_human_papillomaviruses_to_prevent_cervical_cancer_and_its_precursors:_Cochrane_systematic_review. Accessed April 20, 2024.
Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Prophylactic_vaccination_against_human_papillomaviruses_to_prevent_cervical_cancer_and_its_precursors:_Cochrane_systematic_review
Capecitabine for Hormone Receptor‐positive Versus Hormone Receptor‐negative Breast Cancer [Internet]. In: Cochrane Abstracts. [cited 2024 April 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Prophylactic_vaccination_against_human_papillomaviruses_to_prevent_cervical_cancer_and_its_precursors:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer
ID - 438840
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438840/all/Prophylactic_vaccination_against_human_papillomaviruses_to_prevent_cervical_cancer_and_its_precursors:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -